Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

This article is part of the supplement: B cell targeted therapy: a new approach to the treatment of rheumatoid arthritis

Highly Accessed Review

B cell non-Hodgkin's lymphoma: rituximab safety experience

Ann Mohrbacher

Author Affiliations

Division of Hematology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA

Arthritis Research & Therapy 2005, 7(Suppl 3):S19-S25  doi:10.1186/ar1739

Published: 18 May 2005

Abstract

A substantial body of data supports use of rituximab as first-line and maintenance therapy for the treatment of indolent non-Hodgkin's lymphoma. With 7 years of postmarketing surveillance experience and more than 370,000 patient exposures, the safety profile of rituximab is well defined. Several multicenter trials suggest that infusion reactions associated with rituximab administration are well characterized and generally associated with the first infusion; toxicity is reduced with subsequent doses. Since some adverse events are related to circulating tumor loads of non-Hodgkin's lymphoma, fewer events are anticipated in rheumatoid arthritis. Low infection rates in oncology would indicate similar safety in patients with rheumatoid arthritis.